Molbio Diagnostics Seeks ₹940 Crore in IPO for Expansion and Stake Reduction

Molbio Diagnostics, a leading player in the molecular diagnostics sector, is set to launch an Initial Public Offering (IPO) aiming to raise ₹940 crore. The company plans a fresh issue of ₹200 crore to bolster its capital expenditures, while an additional ₹740 crore will be sought through an offer for sale, reducing the promoter group's stake from 46.6% to 43%.

Strategic Expansion and Financial Performance

Founded in 2000, Molbio Diagnostics has been instrumental in developing diagnostic solutions for both infectious and non-communicable diseases. The company operates six manufacturing facilities in India and serves clients in over 90 countries, including government health programs, diagnostic labs, and international healthcare organizations. A significant portion of its revenue, around 74%, is derived from the sale of diagnostic test kits, with tuberculosis kits alone contributing to 70% of this segment.

Financially, Molbio has demonstrated robust growth. Between FY24 and FY26, the company's revenue from operations surged by 31.5% to ₹1,445.7 crore, while net profits increased by 40.2% to ₹164.1 crore. The EBITDA also saw a rise of 33.2%, reaching ₹328.2 crore, with the EBITDA margin improving to 22.6% in FY26 from 22% in FY24.

Market Position and Valuation

Molbio's flagship product, the 'Truenat' platform, is designed for resource-limited settings, providing rapid and accurate test results within an hour. The company's strategic collaborations and subsidiaries further extend its offerings to radiology, digital pathology, and breast health screening solutions.

The IPO's valuation, based on the post-IPO equity and FY26 net profit, suggests a price-earnings (P/E) multiple of up to 57. While Molbio lacks directly comparable listed peers in India, similar companies in the diagnostics and medical device sectors, such as Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre, trade at P/E multiples between 54 and 81.

Investment Considerations

Molbio's revenue heavily relies on its top clients, which contribute over half of the total income, indicating a concentration risk. Moreover, government and international aid agencies account for more than 80% of the company's revenue, underscoring its dependence on external funding sources.

For investors with a high-risk tolerance, Molbio's IPO presents an opportunity for long-term growth, supported by its consistent financial performance and strategic market positioning. However, potential investors should carefully consider the risks associated with customer concentration and reliance on external funding before making investment decisions.